Systematic review of gender bias in clinical trials of monoclonal antibodies for the treatment of multiple sclerosis M. Alonso-Moreno; M. Ladrón-Guevara; P. Ciudad-Gutiérrez;

Progression of a series of patients with relapsing-remitting multiple sclerosis treated for 7 years with natalizumab using the ¿no evidence of disease activity¿ parameter A. Pato Pato; E. Costa Arpín; A. Rodríguez Regal; I. Rodríguez Constenla; I. Cimas Hernando; I. Muñoz Pousa; L. Naya Ríos; J.R. Lorenzo González; M.C. Amigo Jorrín; J.M. Prieto González;

Recommendations for the critical reading of clinical trials on disease-modifying drugs for multiple sclerosis A. Rivero-de-Aguilar; M. Mascareñas-García; M. Pérez-Ríos; M.A. Llaneza-Gonzalez; P. Mulero; M. Mendibe; À. Rovira; V. Meca-Lallana; A.J. García-Ruiz; L. Landete; J.R. Vizoso Hermida; P. Carrascal Rueda; A. Ruano-Raviña; M. Puente-Hernandez; L. Varela-Lema;